Drugs / CAR.K.28
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04223765 | Nov 2020 → Mar 2028 expected | MALT lymphoma, follicular lymphoma, mantle cell lymphoma, nodal marginal zone B-cell lymphoma +1 | UNC Lineberger Comprehensive Cancer Center | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR.K.28 | “Therapy in LCCC1811-ATL involves a single cell infusion of CAR.K.28 cells.” NCT04223765 ↗ |
| Known as | ATLCAR.κ.28 | “The kappa light chain chimeric (combination) receptor-activated T cells are called ATLCAR.κ.28 cells.” NCT04223765 ↗ |
| Action | Deplete | “These cells may be able to destroy lymphoma cancer cells.” NCT04223765 ↗ |
| Modality | Cell therapy | “The cellular product consisting of CAR.κ.28 cells will be administered by a licensed healthcare provider” NCT04223765 ↗ |